Lyka Labs Limited AI Stock Analysis
Want to see IN:LYKALABS full AI Analyst Report?
Lyka Labs Limited (LYKALABS) AI Stock Analysis
Lyka Labs Limited
(NSE:LYKALABS)
The stock’s moderate overall score reflects weak and volatile profitability and cash generation as the dominant concern, despite an improved capital structure, while a currently strong price trend and positive technical setup provide support but are tempered by loss-driven, hard-to-interpret valuation and elevated volatility.
Lyka Labs Limited (LYKALABS) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 3.12B
- Dividend Yield
- ―
- Average Volume (3M)
- 5,317
- Price to Earnings (P/E)
- -71.9
- Beta (1Y)
- 1.25
- Revenue Growth
- 6.10%
- EPS Growth
- -309.17%
- Country
- India
- Employees
- 648
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Lyka Labs Limited Business Overview & Revenue Model
Company Description
Established in 1976 and headquartered in Mumbai, India, Lyka Labs Limited is a pharmaceutical firm specializing in the development, manufacturing, and marketing of a wide array of pharmaceutical formulations and active pharmaceutical ingredients (API...
Lyka Labs Limited Financial Statement Overview
Summary
Overall financial quality is weak: revenue has recently declined, profitability has swung from solid profit to sizeable losses in 2026, and free cash flow has been negative and worsening, partially offset by a meaningfully improved balance sheet with lower debt and positive equity.
Income Statement
32NegativeBalance Sheet
61PositiveCash Flow
28Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.38B | 1.28B | 1.41B | 1.05B | 916.90M | 1.84B |
| Gross Profit | 311.71M | 279.37M | 851.35M | 599.41M | 152.84M | 1.30B |
| EBITDA | -5.41M | -36.57M | 201.67M | 167.59M | 128.47M | 1.01B |
| Net Income | -88.99M | -100.32M | 80.12M | -24.89M | -132.12M | 390.00M |
Balance Sheet | ||||||
| Total Assets | 0 | 1.75B | 1.76B | 1.57B | 1.52B | 1.86B |
| Cash, Cash Equivalents and Short-Term Investments | 18.93M | 13.85M | 13.63M | 62.91M | 119.39M | 170.59M |
| Total Debt | 0 | 488.69M | 391.84M | 586.50M | 751.02M | 1.30B |
| Total Liabilities | -908.31M | 837.05M | 726.24M | 884.59M | 1.06B | 1.72B |
| Stockholders Equity | 908.31M | 923.93M | 1.04B | 681.54M | 454.41M | 133.38M |
Cash Flow | ||||||
| Free Cash Flow | 51.46M | -75.25M | -137.55M | -74.58M | 7.67M | 717.33M |
| Operating Cash Flow | 136.84M | 36.06M | 18.99M | 17.73M | 89.53M | 792.46M |
| Investing Cash Flow | -46.95M | -111.03M | -117.96M | -94.88M | 73.50M | -61.72M |
| Financing Cash Flow | -91.69M | 75.12M | 52.92M | 19.53M | -216.43M | -631.77M |
Lyka Labs Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:LYKALABS, the sentiment is Positive. The current price of 85.50 is above the 20-day moving average (MA) of 81.05, above the 50-day MA of 80.94, and above the 200-day MA of 68.54, indicating a bullish trend. The MACD of 0.73 indicates Negative momentum. The RSI at 63.31 is Neutral, neither overbought nor oversold. The STOCH value of 98.85 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:LYKALABS.
Lyka Labs Limited Peers Comparison
Overall Rating
IN:SUPRIYA68.9Neutral
IN:HALEOSLABS58Neutral
IN:DCAL56Neutral
IN:LYKALABS50.8Neutral
IN:ZOTA45Neutral
IN:PANACEABIO37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 69Neutral | INR 50.11B | 28.27 | ― | 0.16% | 23.00% | -2.84% | |
| 58Neutral | INR 4.99B | 37.78 | ― | 0.09% | -0.99% | -30.72% | |
| 56Neutral | INR 21.91B | 32.01 | ― | ― | -20.86% | -34.51% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 51Neutral | INR 3.09B | -71.92 | ― | ― | 6.10% | -309.17% | |
| 45Neutral | INR 39.06B | -38.39 | ― | 0.08% | 68.95% | -55.82% | |
| 37Underperform | INR 21.51B | -303.10 | ― | ― | 19.43% | ― |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:LYKALABS | Lyka Labs Limited | 85.50 | 2.47 | 2.97% | |
| IN:DCAL | Dishman Carbogen Amcis Ltd. | 139.75 | -108.30 | -43.66% | |
| IN:PANACEABIO | Panacea Biotec Limited | 351.10 | -27.35 | -7.23% | |
| IN:HALEOSLABS | SMS Lifesciences India Ltd. | 1650.90 | 323.00 | 24.32% | |
| IN:SUPRIYA | Supriya Lifescience Limited | 622.65 | -179.70 | -22.40% | |
| IN:ZOTA | Zota Health Care Ltd. | 1287.60 | -285.62 | -18.16% |
Lyka Labs Limited Corporate Events
Lyka Labs Files SEBI Dematerialisation Compliance Certificate for September Quarter
Lyka Labs Limited has submitted to the stock exchanges a compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30 September 2026. The company forwarded a certificate from its...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 26, 2026
